{
    "1650742937536323584": {
        "author_id": "5383942",
        "created_at": "2023-04-25T06:06:00.000Z",
        "edit_history_tweet_ids": [
            "1650742937536323584"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 70,
                    "normalized_text": "EMA",
                    "probability": 0.4576,
                    "start": 68,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 5,
                    "start": 0,
                    "tag": "News"
                },
                {
                    "end": 20,
                    "start": 10,
                    "tag": "Investors"
                },
                {
                    "end": 31,
                    "start": 25,
                    "tag": "Media"
                },
                {
                    "end": 200,
                    "start": 193,
                    "tag": "cancer"
                }
            ]
        },
        "id": "1650742937536323584",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 4173,
            "like_count": 11,
            "quote_count": 1,
            "reply_count": 0,
            "retweet_count": 2
        },
        "text": "#News for #Investors and #Media: We\u2019re pleased to announce that the EMA has accepted the marketing authorisation application for a potential new indication of our immuno-oncology treatment for #cancer patients."
    }
}